Tourmaline Bio, Inc.

Ownership Transactions Reported by 26 Insiders

Symbol
TRML on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
27 West 24 Th Street, Suite 702, New York, NY

Insiders trading volume in the past year

Tourmaline Bio, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Suzanne Ildstad Director $75.2M Jun 12, 2023
Longitude Capital Partners III, LLC 10%+ Owner $54.7M May 11, 2021
Mark Mcdade Director $24.1M +$3.25M +15.6% Jun 5, 2024
Scott Requadt Former Chief Executive Officer $17.5M Jul 3, 2023
Caley Castelein Director $16.6M Jun 5, 2024
Clarus Lifesciences III, L.P. 10%+ Owner $2.72M May 11, 2021
Clarus Defined Exit I, L.P. 10%+ Owner $2.72M May 11, 2021
Parvinder Thiara Director $1.42M Jun 5, 2024
W. Bradford Middlekauff CBO, GC and Secretary $1.18M Oct 19, 2023
Mary Kay Fenton Chief Financial Officer $1.16M Jul 3, 2023
Kevin Bruce Johnson Chief Regulatory Officer $983K Oct 19, 2023
Yung H. Chyung Chief Medical Officer $966K Oct 19, 2023
Aaron Kantoff Director $771K Jun 5, 2024
Susan Dana Jones Chief Technology Officer $390K Oct 19, 2023
Sandeep Chidambar Kulkarni CEO, Director $104K +$98.4K +1778% Aug 21, 2024
Sapna Srivastava Director $8.8K Jun 5, 2024
Karen L. Smith Director Jun 13, 2023
Gaurav Shah Director Jun 13, 2023
Geoffrey Mackay Director Jun 13, 2023
Sandip Agarwala Director Jun 13, 2023
Michael Zdanowski Chief Technology Officer Feb 1, 2023
Nancy Krieger Chief Medical Officer Feb 1, 2023
Francois Nader Director Jun 13, 2023
Cariad Chester Director Oct 19, 2023
Ryan F. Robinson Chief Financial Officer Jun 25, 2024
Clay B. Siegall Director Jun 5, 2024

Recent Insider Transactions by Companies or Individuals for Tourmaline Bio, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.